UP!

ARIA $23.99   View long term graphs

ARIAD Pharmaceuticals, Inc.
Former type
Subsidiary
Traded as NASDAQ: ARIA
Industry Pharmaceuticals, biotechnology
Fate Merged with Takeda Pharmaceuticals
Founded 1991
Defunct 2017
Headquarters Cambridge, MA, United States
Key people
Harvey Berger (CEO)
Alex Denner,
Chairman of the Board
Harvey Berger,
retired (as of December 2015) Chairman & CEO
Timothy P. Clackson,
President of Research and Development and Chief Scientific Officer
Products Ridaforolimus (Under development)
Ponatinib (FDA approved, trade name Iclusig)
Brigatinib (Under development)
Revenue IncreaseUS$178.98M (FY 2010)
Operating income
IncreaseUS$104.90M (FY 2010)
Net income
IncreaseUS$85.25M (FY 2010)
Total assets DecreaseUS$50.4M (FY 2010)
Number of employees
125 (2011)
Website www.ariad.com

ARIAD Pharmaceuticals, Inc. was an American oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On February 16, 2017, Takeda announced it had completed its acquisition of Ariad.

On December 14, 2012 the FDA approved Ariad Pharmaceutical's leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or unable to tolerate other tyrosine kinase therapies on the market. The drug was temporarily withdrawn from the market in November 2013 "because of the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted on December 20, 2013 with ponatinib being issued revised prescribing information, a new "black box warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and benefits of using the drug.

Ariad also has brigatinib, a lung cancer drug which has completed its registration trial in ALK fusion driven non-small cell lung cancer as of June 2016.

In January 2017, Takeda announced it would acquire Ariad for $5.2 billion, expanding the company's oncology and hematology divisions. The acquisition was completed on February 16, 2017.

Ariad is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. Various investigator-sponsored trials are ongoing in several indications, including first line and second line CML, acute lymphoblastic leukemia (BCR-ABL), acute myeloid leukemia (FLT3 inhibitor), non-small cell lung cancer (RET, FGFR), advanced biliary cancer With FGFR2 fusions and other cancers with activating mutations involving the following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, and KIT.

In addition, its product pipeline consists of Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer. This drug reported results of its registration trial at ASCO, June 6, 2016, with encouraging results; AP32788, an inhibitor of solid tumors with EGFR and HER2 activating mutation, which began phase I testing in the second quarter of 2016; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus.

On February 21, 2014 Ariad Pharmaceuticals announced the appointment of Sarissa Capital's Alexander J. Denner, Ph.D. to a two-year term on the company's Board of Directors. Previously, Denner served as a senior managing director at Carl Icahn's Icahn Capital and is currently Ariad's second-largest shareholder. On January 10, 2016, Ariad announced that Denner had become the chairman of the board, replacing Harvey Berger. Shortly thereafter, the company announced the termination of its shareholder's rights plan (the "poison pill.")

In July 2015, the company announced it was due to receive up to $200 million through a royalty financing deal with PDL BioPharma on future sales of ponatinib.

In 2016, the company was ranked #3 on the Deloitte Fast 500 North America list.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2017 2017-05-08 Future report Set alerts
Q4 2016 2017-02-23 Future report Set alerts
Q3 2016 2016-11-07 -0.14 -0.14
Q2 2016 2016-07-28 0.56 0.56
Q1 2016 2016-05-10 -0.28 -0.28
Q4 2015 2016-02-23 -0.32 -0.32
Q3 2015 2015-11-03 -0.29 -0.29
Q2 2015 2015-08-05 -0.33 -0.33
Q1 2015 2015-05-07 -0.28 -0.28
Q4 2014 2015-02-19 -0.03 -0.03

Ratings

2016-06-22 Reiterated Rating Jefferies Group Buy $13.00
2016-06-21 Reiterated Rating Cowen and Company Outperform $10.00
2016-06-20 Reiterated Rating RBC Capital Hold
2016-06-20 Reiterated Rating Royal Bank Of Canada Hold
2016-06-06 Reiterated Rating JMP Securities Buy
2016-06-06 Reiterated Rating Cowen and Company Buy $10.00
2016-05-24 Reiterated Rating William Blair Buy $10.00
2016-05-24 Reiterated Rating Jefferies Group Buy $13.00
2016-05-19 Reiterated Rating Cowen and Company Outperform $10.00
2016-05-12 Reiterated Rating Barclays Sell
2016-05-12 Reiterated Rating Barclays PLC Sell
2016-05-11 Boost Price Target Barclays Underweight $6.00 to $8.00
2016-05-05 Upgrade Cowen and Company Market Perform to Outperform $10.00
2016-04-19 Reiterated Rating JMP Securities Outperform $9.00
2016-04-17 Reiterated Rating Cowen and Company Hold
2016-03-11 Reiterated Rating JPMorgan Chase & Co. Outperform $11.00 to $9.00
2016-03-09 Boost Price Target JPMorgan Chase & Co. Market Outperform $9.00 to $11.00
2016-03-09 Lower Price Target JMP Securities Market Outperform $11.00 to $9.00
2016-02-25 Reiterated Rating RBC Capital Hold
2016-02-22 Lower Price Target Goldman Sachs $7.00 to $5.00
2016-02-22 Lower Price Target Goldman Sachs Group Inc. $7.00 to $5.00
2016-01-19 Initiated Coverage Barclays Underweight $6.00 to $6.00
2015-08-07 Reiterated Rating JPMorgan Chase & Co. Neutral $8.00 to $9.00
2015-07-21 Reiterated Rating Cowen and Company Market Perform
2015-07-20 Boost Price Target Goldman Sachs Neutral $6.00 to $7.00
2015-06-26 Reiterated Rating William Blair Outperform $11.00
2015-06-06 Reiterated Rating William Blair Outperform $11.00
2015-06-05 Reiterated Rating HC Wainwright Buy
2015-05-16 Reiterated Rating BMO Capital Markets Outperform $14.00
2015-05-16 Reiterated Rating Stifel Nicolaus Buy
2015-05-10 Initiated Coverage JPMorgan Chase & Co. Neutral $8.00
2015-04-20 Set Price Target BMO Capital Markets Buy $14.00
2015-02-23 Set Price Target HC Wainwright Buy $10.00
2015-01-07 Set Price Target HC Wainwright Buy $8.00
2014-12-11 Downgrade Credit Suisse Neutral to Underperform $8.00 to $6.00
2014-12-11 Downgrade Credit Suisse Group AG Neutral to Underperform $8.00 to $6.00
2014-11-06 Reiterated Rating Chardan Capital Neutral
2014-08-08 Reiterated Rating Citigroup Inc. Sell $7.00 to $5.00
2014-08-07 Lower Price Target JMP Securities Market Outperform $8.00 to $7.00
2014-08-07 Reiterated Rating Chardan Capital Buy
2014-06-02 Reiterated Rating Jefferies Group Positive
2014-05-08 Reiterated Rating JMP Securities Market Outperform $10.00 to $8.00
2014-05-05 Upgrade Jefferies Group Hold to Buy $8.00 to $14.00
2014-03-26 Reiterated Rating BMO Capital Markets Positive
2014-03-25 Initiated Coverage HC Wainwright Neutral to Buy $14.00
2014-02-27 Reiterated Rating Goldman Sachs Hold to Neutral
2014-02-26 Upgrade Maxim Group Hold to Buy $11.00
2014-02-26 Downgrade Chardan Capital Markets Buy to Neutral
2014-02-26 Boost Price Target Citigroup Inc. $5.50 to $7.00
2014-02-26 Downgrade Chardan Capital Buy to Neutral $9.00
2014-02-26 Boost Price Target Jefferies Group $7.00 to $8.00
2014-02-07 Set Price Target Credit Suisse $5.00 to $8.00
2014-01-24 Upgrade BMO Capital Markets Market Perform to Outperform $8.00 to $14.00
2014-01-13 Reiterated Rating JMP Securities Outperform $10.00
2014-01-06 Downgrade Citigroup Inc. Neutral to Sell $2.50 to $5.50
2013-12-23 Upgrade Chardan Capital Markets Neutral to Buy $9
2013-12-23 Reiterated Rating Bank of America Underperform $2.00 to $3.00
2013-12-23 Reiterated Rating Credit Suisse Buy to Neutral $2.50 to $5.00
2013-12-23 Upgrade Chardan Capital Neutral to Buy $9.00
2013-12-23 Upgrade William Blair Market Perform to Outperform $3.00 to $12.00
2013-12-20 Boost Price Target Guggenheim Neutral $3.00 to $6.00
2013-12-20 Boost Price Target Cowen and Company Market Perform $2.50 to $4.00
2013-12-20 Upgrade JMP Securities Market Perform to Outperform $10.00
2013-12-20 Boost Price Target BMO Capital Markets Market Perform $4.00 to $8.00
2013-12-10 Upgrade Stifel Hold to Buy $7
2013-12-10 Upgrade Stifel Nicolaus Hold to Buy $7.00
2013-11-12 Reiterated Rating Goldman Sachs Neutral
2013-11-01 Lower Price Target Credit Suisse Neutral $4.00 to $2.50
2013-11-01 Lower Price Target BMO Capital Markets $8.00 to $2.50
2013-11-01 Downgrade Leerink Swann Outperform to Market Perform $7.00 to $2.50
2013-11-01 Downgrade Jefferies Group Buy to Hold $7.00 to $2.50
2013-10-31 Downgrade Cowen and Company Outperform to Market Perform $10.00 to $2.50
2013-10-31 Downgrade Guggenheim Buy to Neutral $7.00 to $3.00
2013-10-23 Downgrade Lazard Capital Markets Buy to Neutral
2013-10-21 Downgrade HC Wainwright Buy to Neutral $2.50
2013-10-21 Reiterated Rating Jefferies Group Buy $7.00
2013-10-21 Downgrade Oppenheimer Outperform to Market Perform $7.00
2013-10-21 Downgrade William Blair Outperform to Market Perform
2013-10-18 Lower Price Target Guggenheim Buy $10.00 to $7.00
2013-10-18 Downgrade RBC Capital Outperform to Sector Perform $9.00 to $4.00
2013-10-18 Downgrade JPMorgan Chase & Co. Overweight to Neutral
2013-10-14 Downgrade Argus Hold to Sell
2013-10-11 Lower Price Target Credit Suisse Neutral $20.00 to $6.00
2013-10-10 Lower Price Target Oppenheimer Outperform $24.00 to $7.00
2013-10-10 Downgrade Summer Street Research Buy to Neutral
2013-10-10 Downgrade Chardan Capital Markets Buy to Neutral
2013-10-10 Downgrade Barclays Overweight to Underweight $25.00 to $4.00
2013-10-10 Lower Price Target William Blair Outperform $26.00 to $7.00
2013-10-10 Lower Price Target RBC Capital Outperform $28.00 to $9.00
2013-10-10 Lower Price Target Guggenheim Buy $28.00 to $10.00
2013-10-10 Lower Price Target Leerink Swann Outperform $28.00 to $9.00
2013-10-10 Downgrade Summer Street Buy to Neutral
2013-10-10 Downgrade Chardan Capital Buy to Neutral $26.00
2013-10-10 Downgrade Citigroup Inc. Buy to Neutral
2013-10-10 Downgrade JMP Securities Outperform to Market Perform
2013-10-09 Lower Price Target Jefferies Group Buy $23.00 to $7.00
2013-10-09 Lower Price Target Cowen and Company Hold $27.50 to $10.00
2013-10-09 Lower Price Target BMO Capital Markets Market Perform $21.00 to $8.00
2013-10-09 Downgrade Maxim Group Buy to Hold $24.00
2013-10-09 Downgrade Bank of America Buy to Neutral $24.00 to $7.00
2013-10-09 Downgrade Brean Capital Buy to Hold
2013-10-09 Downgrade Stifel Nicolaus Buy to Hold
2013-09-30 Upgrade Oppenheimer Market Perform to Outperform $23.00 to $24.00
2013-09-30 Lower Price Target JMP Securities Market Outperform $30.00
2013-09-30 Lower Price Target Brean Capital Buy $28.00 to $26.00
2013-09-30 Lower Price Target Maxim Group Buy $26.00 to $24.00
2013-09-30 Downgrade BMO Capital Markets Outperform to Market Perform $37.00 to $21.00
2013-09-18 Boost Price Target Goldman Sachs $20.00 to $21.00
2013-09-04 Initiated Chardan Capital Markets Buy $28
2013-02-26 Reiterated Barclays Overweight $30 to $29
2016-06-22 Reiterated Rating Jefferies Group Buy $13.00
2016-06-21 Reiterated Rating Cowen and Company Outperform $10.00
2016-06-20 Reiterated Rating RBC Capital Hold
2016-06-20 Reiterated Rating Royal Bank Of Canada Hold
2016-06-06 Reiterated Rating JMP Securities Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
BERGER HARVEY J M D Chairman & CEO 0.93%  (1732111) ARIA /
LAMARCHE JAY R 0.30%  (552205) ARIA /
FITZGERALD EDWARD M Executive VP, CFO 0.17%  (320367) ARIA /
BERSTEIN DAVID L Senior VP, Chief IP Officer 0.14%  (262115) ARIA /
Haluska Frank SVP, Clinical R&D, CMO 0.08%  (158711) ARIA /
Cantor Maria E SVP, Corporate Affairs 0.08%  (144667) ARIA / QURE /
LAVIDAS ATHANESE 0.07%  (131631) ARIA /
WILSON WAYNE 0.06%  (113000) ARIA / CNSL / EDGW / FRP / HOLX /
Radaelli Massimo 0.06%  (105500) ARIA / NBY /
Duvall Martin J SVP, Commercial Operations 0.06%  (105189) ARIA / TOCA /
DODION PIERRE F SVP, Corp. Dev. & Operations 0.05%  (102532) ARIA /
Keane Raymond T SVP General Counsel & CCO 0.03%  (62096) ARIA /
Whelan, Jr. Robert M. 0.02%  (44859) ARIA / AZPN /
DesRosier Thomas EVP, General Counsel 0.02%  (36630) ARIA / CBST /

Comments